# US 2020/0368314 A1 · Peptides for treatment and prevention of nonalcoholic fatty liver disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0368314 A1
- Document ID: US20200368314A1
- Status: Published application
- Kind: A1
- Application number: 16/636,040
- Filed: 2018-08-03
- Published: 2020-11-26
- Earliest claimed: 2017-08-03
- Assignees: Universite De Strasbourg; Inserm (Institut National De La Sante Et De La Recherche Medicale); Vaxine Pty Ltd
- Applicants: Universite De Strasbourg; Inserm (Institut National De La Santé Et De La Recherche MéDicale); Vaxine Pty Ltd
- Inventors: VINCENT MARION; NIKOLAI PETROVSKY
- Web page: https://patentgrep.com/patent/US20200368314A1

## CPC

- A61K 38/16: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)}
- A61K 38/45: Transferases (2)
- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 38/10: Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- C12N 9/1205: {Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases}
- C12Y 207/11013: Protein kinase C (2.7.11.13)
- A61K 2300/00: Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

The present invention relates to peptides for the treatment or prevention of nonalcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), hepatic steatosis (fatty liver), liver fibrosis, liver inflammation, cirrhosis, or hepatocellular carcinoma.

## Claims

### Claim at position 1

1-15. (canceled)

### Claim 16

A method of treating a disease selected from the group consisting of nonalcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), hepatic steatosis (fatty liver), liver fibrosis, liver inflammation, cirrhosis, or hepatocellular carcinoma comprising the administration of a peptide to a subject having a disease selected from the group consisting of nonalcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), hepatic steatosis (fatty liver), liver fibrosis, liver inflammation, cirrhosis, or hepatocellular carcinoma, wherein:
the peptide modifies the expression levels of the FATPs expression in adipose tissue;
the peptide sequence is a segment of at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 25 consecutive residues of a protein kinase C (PKC);
the peptide contains at least one methionine, one proline and one arginine;
the peptide has a length of:
a) at least 8 amino acids and less than 40 amino acids;
b) a length of at least 10 amino acids and less than 30 amino acids; or
c) a length of at least 12 amino acids and less than 25 amino acids; and
the peptide may comprise 1, 2, 3, 4, or 5 modification(s) of an amino acid selected from substitution(s), deletion(s), addition(s), and a mixture thereof within said sequence of a segment of a PKC.

### Claim 17 (depends on 16)

The method according to claim 16, wherein the peptide adopts an alpha helical conformation.

### Claim 18 (depends on 16)

The method according to claim 16, wherein the peptide is modified by a chemical cross-linking process.

### Claim 19 (depends on 16)

The method according to claim 16, wherein the peptide is a sequence according to one of the following formulae:
M-(X)m-P-(X)n-R;
M-(X)m-R-(X)n-P;
P-(X)m-M-(X)n-R;
P-(X)m-R-(X)n-M;
R-(X)m-P-(X)n-M; or
R-(X)m-M-(X)n-P,
wherein m and n are integers from 1 to 20, m+n is less than 30 and X is any amino acid.

### Claim 20 (depends on 19)

The method according to claim 19, wherein the peptide is a sequence according to one of the following formulae:
M-(X)m-R-(X)n-P;
P-(X)m-R-(X)n-M;
R-(X)m-M-(X)n-P; or
M-(X)m-P-(X)n-R,
wherein m and n are integers from 1 to 20, m+n is less than 30 and X is any amino acid.

### Claim 21 (depends on 19)

The method according to claim 19, wherein m+n is less than 20 and m and n are an integer from 2 to 15.

### Claim 22 (depends on 16)

The method according to claim 16, wherein said PKC is selected from the group consisting of an alpha-PKC (αPKC), a beta-PKC (βPKC), βI PKC, βII PKC, delta-PKC, theta-PKC, eta-PKC and epsilon-PKC.

### Claim 23 (depends on 22)

The method according to claim 22, wherein said PKC is an αPKC comprising SEQ ID No 1.

### Claim 24 (depends on 16)

The method according to claim 16, wherein the peptide is selected from the group consisting of:
(SEQ ID No 2)
MVEKRVLALLDKP;
(SEQ ID No 3)
PFLTQLHSCFQTVDRLYFVM;
(SEQ ID No 4)
RLYFVMEYVNGGDLMYHIQQVGKFKEP;
(SEQ ID No 5)
MYHIQQVGKFKEPQAVFYAAEISIGLFFLHKR;
(SEQ ID No 6)
PQAVFYAAEISIGLFFLHKRGIIYRDLKLDNVM;
(SEQ ID No 7)
MDGVTTRTFCGTP;
and
(SEQ ID No 8)
MTKHPAKR;
and optionally it comprises 1, 2, 3, 4, or 5 modification(s) of an amino acid selected from substitution(s), deletion(s), addition(s), and a mixture thereof.

### Claim 25 (depends on 24)

The method according to claim 24, wherein the peptide is selected from the group consisting of:
(SEQ ID No 2)
MVEKRVLALLDKP;
(SEQ ID No 7)
MDGVTTRTFCGTP;
and
(SEQ ID No 8)
MTKHPAKR;
and optionally it comprises 1, 2, 3, 4, or 5 modification(s) of an amino acid selected from substitution(s), deletion(s), addition(s), and a mixture thereof.

### Claim 26 (depends on 16)

The method according to claim 16, wherein the peptide is selected from the group consisting of:
(SEQ ID No 9)
VECTMVEKRVLALLDKPPFLTQLHS;
(SEQ ID No 10)
MCKEHMMDGVTTRTFCGTPD;
and
(SEQ ID No 11)
SICKGLMTKHPAKRLGCGPEG;
and optionally it comprises 1, 2, 3, 4, or 5 modification(s) of an amino acid selected from substitution(s), deletion(s), addition(s), and a mixture thereof.

### Claim 27 (depends on 16)

The method according to claim 16, wherein the peptide is selected from the group consisting of:
(SEQ ID No 9)
VECTMVEKRVLALLDKPPFLTQLHS;
(SEQ ID No 10)
MCKEHMMDGVTTRTFCGTPD;
and
(SEQ ID No 11)
SICKGLMTKHPAKRLGCGPEG;
wherein the residues which are bold and underlined carry the stapling.

### Claim 28 (depends on 16)

The method according to claim 16, wherein the disease is selected from the group consisting of nonalcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), and hepatic steatosis (fatty liver).

### Claim 29 (depends on 28)

The method according to claim 28, wherein the disease is hepatic steatosis (fatty liver) or non-alcoholic steatohepatitis (NASH).

### Claim 30 (depends on 29)

The method according to claim 29, wherein the disease is non-alcoholic steatohepatitis (NASH).

### Claim 31 (depends on 16)

The method according to claim 16, said peptide decreasing FATP2 expression in adipose tissue.

### Claim 32 (depends on 21)

The method according to claim 21, wherein m and n are an integer from 2 to 7.
